Compare Alibaba Group (BABA) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs Revvity Inc — how do they compare? Alibaba Group trades at $124.79 (market cap $308.93B), while Revvity Inc trades at $115.25 (market cap $12.91B). The key difference: Alibaba Group is far larger — about 23.9× Revvity Inc's market cap, and Alibaba Group pays the higher dividend (0.82%). Which is the better fit depends on your goals.
| BABA | RVTY | |
|---|---|---|
Market Cap | $308.93B | $12.91B |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $189.34 | $117.75 |
52-Week Low | $94.83 | $82.26 |
Enterprise Value | $303.72B | $15.23B |
Dividend Yield | 0.82% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BABA trades at $132.32, up 3.04% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong 2025 results with $996.35B revenue and $130.11B net income, though recent quarterly EPS misses raise concerns. Analyst consensus remains strongly bullish with an $195.00 price target, but multiple class action lawsuits filed in August 2026 create significant legal overhang.
BABA presents a mixed investment case with strong fundamentals and Wall Street support offset by legal risks and earnings volatility. The stock trades at reasonable valuations (P/E 19.61, P/S 2.03) with solid profitability metrics, but investors must weigh the substantial legal challenges against the company's operational strength and growth trajectory.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
